apremilast / Generic mfg. - LARVOL DELTA

Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial. (PubMed, Dermatol Ther (Heidelb)) - P3 | "Side effects were mainly mild to moderate. The results from this phase 3 study support apremilast as a systemic oral treatment option for patients with PPP with inadequate response to topical treatment, for whom treatment options are limited."

Journal • P3 data • Immunology • Infectious Disease • Pain • Psoriasis

Anti-CD19 chimeric antigen receptor T-cell therapy for patients with non-Hodgkin's lymphoma and concurrent autoimmune disease (ASH 2025) - "methotrexate, hydroxychloroquine (HCQ),azathioprine); 9 required biologic/targeted DMARD (ex. adalimumab, etanercept, risankizumab,infliximab, rituximab).DMARDs were weaned prior to CART however 9 pts (37.5%) remained on AID tx at the time of cellcollection, including HCQ (n=4), sulfasalazine/mesalamine (n=2), and 1 each of prednisone, colestipol,sulfasalazine, and apremilast... In this single center study of pts receiving CART for NHL we found no difference in responserates nor survival outcomes in pts with or without AID and therefore propose that AID should notpreclude the use of CART. Lower severity of ICANS was seen in AID pts, though additional study withlarger cohorts is required. The majority of pts were able to taper off AID tx prior to CART, while HCQ wasable to be safely continued throughout CART collection with no apparent effect on CART efficacy."

CAR T-Cell Therapy • Clinical • Ankylosing Spondylitis • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Dermatology • Dermatomyositis • Gastroenterology • Hematological Disorders • Hematological Malignancies • Immunology • Inflammatory Arthritis • Lymphoma • Myasthenia Gravis • Myositis • Non-Hodgkin’s Lymphoma • Psoriasis • Rheumatoid Arthritis • Rheumatology • Seronegative Spondyloarthropathies

P086 Management of severe psoriasis in patients with concomitant malignancy: a retrospective observational study. (PubMed, Br J Dermatol) - "Prior psoriasis treatments included ultraviolet B phototherapy, methotrexate, ciclosporin and acitretin. At cancer diagnosis, 10 patients (20%) were on tumour necrosis factor (TNF)-α inhibitors, 8 (16%) on interleukin (IL)-17 inhibitors, five (10%) on IL-12/23 inhibitors, 5 (10%) on IL-23 inhibitors, 6 (12%) on methotrexate, 2 (4%) on apremilast and 1 (2%) on ciclosporin...Multidisciplinary collaboration and shared decision making are essential. Clinicians should consider biologic therapies for patients with both malignancy and uncontrolled psoriasis, tailoring treatments to patient-specific factors and malignancy type."

Journal • Observational data • Retrospective data • Breast Cancer • Colon Cancer • Colorectal Cancer • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Psoriasis • Rectal Cancer • Solid Tumor • IL12A • IL17A • IL23A

O07 Serious infection risk with systemic treatments for psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). (PubMed, Br J Dermatol) - "Inclusion criteria were adults who received at least one of the biologics, apremilast or conventional nonbiologics (acitretin, ciclosporin and methotrexate) for ≥ 6 months. All biologics licensed for psoriasis were analysed except for infliximab, which had higher prescription criteria...The certolizumab group had a low mean age of 37.4 years (SD 10.3), the ustekinumab group had a significantly longer median treatment duration of over 4 years (IQR 1.83-6.73), and more patients in the ixekizumab (42.6%) and certolizumab (40.6%) groups had concomitant psoriatic arthritis...IRs (95% CIs) of other tumour necrosis factor-α inhibitors were 15.7 (14.5-17.1) for adalimumab and 16.7 (13.8-20.0) for etanercept. For interleukin-17 inhibitors the IRs (95% CIs) were 18.4 (15.9-21.2) for secukinumab, 7.63 (0.92-27.6) for bimekizumab, 14.5 (7.73-24.8) for brodalumab and 18.5 (14.0-24.0) for ixekizumab. For interleukin-23 inhibitors the IRs (95% CIs) were 13.5 (9.97-17.8) for guselkumab,..."

Journal • Observational data • Dermatology • Immunology • Infectious Disease • Inflammatory Arthritis • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL12A • IL17A

P070 Effect of insulin resistance on treatment response in moderate-to-severe psoriasis: a retrospective study. (PubMed, Br J Dermatol) - "Twenty-four patients received methotrexate and 10 patients received apremilast. However, our study has limitations such as the small sample size and retrospective design. Thus, prospective studies with larger patient populations are needed to evaluate the long-term impact of IR in psoriasis."

Journal • Retrospective data • Dermatology • Immunology • Inflammatory Arthritis • Metabolic Disorders • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

P114 Efficacy and safety of oral Janus kinase, tyrosine kinase 2 and phosphodiesterase 4 inhibitors in the treatment of chronic plaque psoriasis: a network meta-analysis. (PubMed, Br J Dermatol) - "After 16-24 weeks of treatment, tofacitinib and deucravacitinib had the highest efficacy, followed by apremilast, orismilast, upadacitinib and brepocitinib. Zasocitinib, a new highly selective allosteric TYK2 inhibitor, has recently demonstrated promising efficacy in the treatment of psoriasis, with 33% of patients achieving PASI 100 (complete clearance of psoriasis lesions) after just 12 weeks of treatment. In conclusion, oral TYK2 inhibitors have shown efficacy in the treatment of chronic plaque psoriasis comparable with adalimumab, with newer agents demonstrating enhanced effectiveness and surpassing PDE-4 inhibitors in therapeutic outcomes. JAK inhibitors, particularly tofacitinib, exhibit comparable efficacy to some TYK2 and PDE-4 inhibitors."

Clinical • Journal • Retrospective data • Review • Dermatology • Immunology • Psoriasis • TYK2

P085 Prescribing practices among psoriasis experts for patients with concomitant malignancy: a survey of international psoriasis council members. (PubMed, Br J Dermatol) - "This study highlights significant variability in prescribing practices and a strong preference for biologics such as anti-interleukin-17 agents and apremilast. The findings underscore the urgent need for malignancy-specific guidelines informed by robust long-term safety data to support optimal decision making and improve patient outcomes."

Journal • Breast Cancer • Dermatology • Genito-urinary Cancer • Hematological Malignancies • Immunology • Lymphoma • Melanoma • Oncology • Prostate Cancer • Psoriasis • Renal Cell Carcinoma • Solid Tumor

BI07 (P086) Management of severe psoriasis in patients with concomitant malignancy: a retrospective observational study. (PubMed, Br J Dermatol) - "Prior psoriasis treatments included ultraviolet B phototherapy, methotrexate, ciclosporin and acitretin. At cancer diagnosis, 10 patients (20%) were on tumour necrosis factor (TNF)-α inhibitors, eight (16%) on interleukin (IL)-17 inhibitors, five (10%) on IL-12/23 inhibitors, five (10%) on IL-23 inhibitors, six (12%) on methotrexate, two (4%) on apremilast and one (2%) on ciclosporin...Multidisciplinary collaboration and shared decision making are essential. Clinicians should consider biologic therapies for patients with both malignancy and uncontrolled psoriasis, tailoring treatments to patient-specific factors and malignancy type."

Journal • Observational data • Retrospective data • Breast Cancer • Colon Cancer • Colorectal Cancer • Dermatology • Hematological Malignancies • Immunology • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Psoriasis • Rectal Cancer • Solid Tumor • IL12A • IL17A • IL23A

BI33 Expect the unexpected. (PubMed, Br J Dermatol) - "After not responding to topical treatments and apremilast, and experiencing short-term remission with phototherapy, he began treatment with methotrexate in consultation with rheumatologists...He was prescribed tamoxifen for the following 5 years...This research is crucial for the development of early detection and prevention strategies. Finally, patients diagnosed with melanoma should continue regular surveillance, not only for potential melanoma recurrence but also to detect new primary cancers."

Journal • Breast Cancer • Cutaneous Melanoma • Dermatology • Immunology • Inflammatory Arthritis • Melanoma • Oncology • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Solid Tumor • BRCA2 • CDKN2A

The impact of apremilast on cardiometabolic and inflammation indexes in psoriatic patients at high cardiovascular risk: A real-world multicenter retrospective observational study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Observational data • Real-world evidence • Retrospective data • Cardiovascular • Dermatology • Immunology • Inflammation • Psoriasis

Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis. (PubMed, J Eur Acad Dermatol Venereol) - P3 | "Apremilast is an effective oral systemic therapy in patients with moderate to severe genital psoriasis and has shown consistent clinical efficacy, lessening of symptoms and quality-of-life benefit in DISCREET."

Clinical • Journal • P3 data • Dermatology • Immunology • Pain • Psoriasis

Deucravacitinib in Plaque Psoriasis After Inadequate Response to Apremilast: Phase 3 POETYK Analysis. (PubMed, Dermatol Ther (Heidelb)) - P3 | "Deucravacitinib was efficacious in patients with moderate-to-severe plaque psoriasis who did not respond to apremilast."

Journal • P3 data • Dermatology • Immunology • Psoriasis

Effectiveness of Tofacitinib in Patients with Psoriatic Arthritis Initiating Monotherapy Versus Combination Therapy: Results from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. (PubMed, Rheumatol Ther) - P | "Monotherapy and combination therapy initiators demonstrated improvements across effectiveness outcomes. Tofacitinib monotherapy initiators experienced numerical improvements in overall work impairment/activity impairment. This highlights tofacitinib effectiveness as monotherapy/combination therapy for a diverse PsA population. However, the small sample size limited the statistical power, and so results should be interpreted cautiously."

Journal • Monotherapy • Ankylosing Spondylitis • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • Spondylarthritis

Apremilast, Methotrexate and NB-UVB Phototherapy for Moderate to Severe Psoriasis: Efficacy, Safety, and Immunomodulation in Comparison. (PubMed, Photodermatol Photoimmunol Photomed) - "APRE, MTX, and NB-UVB each improved clinical outcomes with comparable overall efficacy and good tolerability in this pilot cohort. Each therapeutic regime showed distinct immunomodulatory profiles with good tolerability. Personalized treatment strategies, including potential combinations, may optimize outcomes for patients with moderate-to-severe psoriasis."

Clinical • Journal • Observational data • Dermatology • Immunology • Inflammation • Psoriasis • IL10 • IL33

Efficacy and Safety of add-on Apremilast Versus add-on Methotrexate in Patients With Oral Lichen Planus (clinicaltrials.gov) - P4 | N=64 | Completed | Sponsor: All India Institute of Medical Sciences, Bhubaneswar | Recruiting ➔ Completed

Trial completion • Dermatology • Dermatopathology • Lichen Planus

Sequential Use of Apremilast, Total Glucosides of Paeony, and Periodontal Therapy in Refractory Plurimucosal Lichen Planus: A Case Report. (PubMed, Case Rep Dent) - "This report presents a 61-year-old female with refractory LP involving buccal, gingival, and vulvovaginal mucosa, unresponsive to prior therapies including corticosteroids and hydroxychloroquine. This case suggests that sequential therapy with apremilast and total glucosides of paeony may be a promising option for managing refractory LP involving multiple mucosal sites. Strategically timed periodontal intervention, initiated after systemic control, improved tolerability and underscored the value of a sequential, multidisciplinary approach."

Journal • Dermatology • Dermatopathology • Inflammation • Lichen Planus

Drug-induced headache reports: a comprehensive disproportionality and time-to-onset pharmacovigilance study using the FAERS database (2018-2024). (PubMed, Front Pain Res (Lausanne)) - "The drugs with the highest headache risk based on ROR included glecaprevir/pibrentasvir (ROR = 10.445), sofosbuvir/velpatasvir (ROR = 9.729), and eptinezumab-jjmr (ROR = 6.775). Top frequently reported drugs were apremilast, treprostinil, and adalimumab...Early-onset headaches (≤7days) were particularly associated with ofatumumab and fingolimod. Late-onset headaches (>90days) were linked to treprostinil and infliximab-dyyb. This large-scale pharmacovigilance study identifies multiple drugs and therapeutic classes with significant associations to headache as an ADR. These findings highlight the need for proactive headache monitoring, particularly during early treatment phases, and warrant further prospective investigations to understand mechanisms and preventive strategies."

Adverse events • Journal • Pain

Inhibition of Structural Damage Progression With Guselkumab, a Selective IL-23i, in Participants With Active PsA: Results Through Week 24 of the Phase 3b APEX Study (ISDS 2025) - P3 | "APEX enrolled biologic-naïve adults with active PsA and ≥2 erosive joints on hand/foot radiographs, despite previous non-biologic DMARDs/apremilast/NSAIDs. No new safety signals were identified. APEX showed significant inhibition of structural damage progression with both dosing regimens of GUS The GUS safety profile in these biologic-naïve pts with active PsA is consistent with that previously established for GUS across a broad range of patients with PsA, psoriasis, and/or inflammatory bowel disease."

P3 data • Dermatology • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies

Roflumilast as an Emerging Treatment for Oral Lichen Planus: A Case Series (ISDS 2025) - "Management typically relies on off-label medications such as topical corticosteroids (TCS), systemic corticosteroids, calcineurin inhibitors (TCI), oral retinoids, and cyclosporine. Phosphodiesterase-4 (PDE-4) inhibitors, including apremilast and roflumilast, have recently been explored for OLP...Case Series: We present three cases of OLP in patients aged 65, 66, and 69, each with recurrent flares after multiple prior therapies, including TCS, TCI, hydroxychloroquine, and minoxidil...Adjunctive therapy included isotretinoin in two cases and topical tacrolimus swish and spit in the third case... This case series suggests that OR may be an effective treatment option for OLP. Further studies are warranted, as only one prior investigation of OR in OLP exists."

Clinical • Anorexia • Dermatitis • Dermatology • Dermatopathology • Gastrointestinal Disorder • Immunology • Inflammation • Lichen Planus • Movement Disorders • Mucositis • Pruritus • CD8

Common Psoriasis Therapeutics and Ocular Symptoms: Analysis of the FAERS Database (ISDS 2025) - "OAE for adalimumab, apremilast, etanercept, infliximab, ustekinumab, guselkumab, and secukinumab were queried from the FAERS Database with disproportionality analysis (DA) conducted for top 25 OAEs. Apremilast, however, was only associated with increased risk of blepharospasm (16.43); all other adverse events studied displayed no increased risk. Our findings support the necessity of physician guidance and the research needed in elucidating ocular adverse events."

Age-related Macular Degeneration • Cataract • CNS Disorders • Dermatology • Dry Eye Disease • Glaucoma • Immunology • Keratitis • Macular Degeneration • Ocular Inflammation • Ophthalmology • Psoriasis • Retinal Disorders • Uveitis • ROR1

Integrative Bioinformatics Analysis Reveals Key Regulatory Genes and Therapeutic Targets in Ulcerative Colitis Pathogenesis. (PubMed, Genes (Basel)) - "In conclusion, this study enhances our understanding of ulcerative colitis pathogenesis by identifying key biomarkers and therapeutic targets, paving the way for future advancements in personalized diagnosis and treatment strategies."

Biomarker • Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Targeted Protein Degradation • Ulcerative Colitis • CD163 • CXCL9 • FOXC1 • FPR2 • GATA2 • IFNG • MIR23A • MIR26A1 • MIR335 • MIR34A • PPARG • PRF1 • TLR2 • TLR8

TAK-279-3002: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period (clinicaltrials.gov) - P3 | N=1108 | Completed | Sponsor: Takeda | Active, not recruiting ➔ Completed

Trial completion • Dermatology • Immunology • Psoriasis

Apremilast in Japanese patients with palmoplantar pustulosis: A randomized, Phase 3 trial. (PubMed, J Eur Acad Dermatol Venereol) - P3 | "In this Phase 3 trial, apremilast was effective in Japanese patients with moderate to severe PPP. Adverse events were consistent with the known safety profile of apremilast."

Journal • P3 data • CNS Disorders • Depression • Dermatitis • Dermatology • Immunology • Pain • Psoriasis • Psychiatry

Medicare announces price cuts for…prescription drugs… (MSN News) - "Here are the negotiated prices for the drugs, based on a 30-day supply, compared to the 2024 list price:...(i) Otezla, a psoriatic arthritis drug: $1,650, down from $4,722...; (ii) Austedo and Austedo XR, for Huntington’s disease: $4,093, down from $6,623."

Commercial • Huntington's Disease • Psoriatic Arthritis

Intensive biological DMARD-first strategy versus standard step-up care in psoriatic arthritis (STAMP): 1-year results from a multicentre, open-label, randomised controlled trial comparing two treat-to-target strategies. (PubMed, Lancet Rheumatol) - "Early use of intensive treatment with secukinumab in a treat-to-target strategy did not result in statistically superior outcomes compared with a conventional step-up treat-to-target approach. By month 12, both strategies led to similar clinical improvements, with half of patients attaining ACR50, suggesting that treatment targets can be met regardless of initial therapy."

Journal • Immunology • Inflammatory Arthritis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL17A